Quidel Announces Modification of Revenue Reporting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
113
Quidel Announces Modification of Revenue Reporting Categories

SAN DIEGO, CA --(Marketwired - January 23, 2017) - Quidel Corporation ( NASDAQ : QDEL ), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will modify its presentation of the components of its major revenue categories.

During the fourth quarter of 2016, Quidel (the "company") modified its presentation of revenue to reflect how management strategically thinks about the business categories. In association with the change, the revenues of QuickVue® and Sofia® businesses will be reported within the company's Immunoassay category, and the revenues of Solana®, AmpliVue® and Lyra® products will be reported in the company's Molecular category. Quidel's Thyretain® and Diagnostic Hybrids, or DHI, revenues will be reported in the company's Virology category, and the Specialty Products Group, or SPG, businesses will be reported in the company's Specialty Products category.

"Our traditional reporting categories, such as Infectious Disease and Women's Health, for example, were historically useful, but this new approach we believe more accurately reflects how we think about the strategic components of the broader business, especially key pieces of the business, like our Immunoassay or Molecular product categories," said Douglas Bryant, president and chief executive officer of Quidel Corporation.

The following tables provide a recast of the components of quarterly revenue for the periods ended March 31, 2014 through September 30, 2016 and for the fiscal years ended December 31, 2014 and 2015. This information will be presented in future filings on the Company's Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for applicable comparable periods.

     
    2016
(in thousands)   First Quarter   Second Quarter   Third Quarter   2016 YTD
Immunoassays   $ 32,503   $ 21,848   $ 30,573   $ 84,924
Molecular     2,108     2,236     2,469     6,813
Virology     10,840     9,861     9,354     30,055
Specialty products     2,408     3,258     2,721     8,387
Royalties, grants and other     2,462     1,930     4,224     8,616
    $ 50,321   $ 39,133   $ 49,341   $ 138,795
                         
    2015
(in thousands)   First Quarter   Second Quarter   Third Quarter   Fourth Quarter   Total
Immunoassays   $ 43,898   $ 19,475   $ 32,224   $ 34,751   $ 130,348
Molecular     1,232     1,397     1,232     1,563     5,424
Virology     12,418     10,301     9,662     11,366     43,747
Specialty products     2,373     2,078     2,246     2,304     9,001
Royalties, grants and other     1,780     1,953     1,448     2,428     7,609
    $ 61,701   $ 35,204   $ 46,812   $ 52,412   $ 196,129
       
    2014
(in thousands)   First Quarter   Second Quarter   Third Quarter   Fourth Quarter   Total
Immunoassays   $ 30,233   $ 16,990   $ 24,395   $ 47,097   $ 118,715
Molecular     695     894     811     1,018     3,418
Virology     12,816     10,630     9,779     11,546     44,771
Specialty products     1,819     1,962     2,086     1,912     7,779
Royalties, grants and other     1,566     1,407     4,122     2,380     9,475
    $ 47,129   $ 31,883   $ 41,193   $ 63,953   $ 184,158
                               

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct Detection and Thyretain® leading brand names, as well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza , respiratory syncytial virus , Strep A, herpes, pregnancy, thyroid disease and fecal occult blood . Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit quidel.com .

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, revenue estimates in this press release are preliminary and subject to change; fluctuations in our operating results resulting from seasonality, the timing of the onset, length and severity of cold and flu seasons, government and media attention focused on influenza and the related potential impact on humans from novel influenza viruses, adverse changes in competitive conditions in domestic and international markets, changes in sales levels as it relates to the absorption of our fixed costs, lower than anticipated market penetration of our products, the reimbursement system currently in place and future changes to that system, changes in economic conditions in our domestic and international markets, the quantity of our product in our distributors' inventory or distribution channels, changes in the buying patterns of our distributors, and changes in the healthcare market and consolidation of our customer base; our development and protection of intellectual property; our development of new technologies, products and markets; our reliance on a limited number of key distributors; our reliance on sales of our influenza diagnostics tests; our ability to manage our growth strategy, including our ability to integrate companies or technologies we have acquired or may acquire; intellectual property risks, including but not limited to, infringement litigation; our debt service requirements; our inability to settle conversions of our convertible senior notes in cash; the effect on our operating results from the trigger of the conditional conversion feature of our convertible senior notes; our need for additional funds to finance our operating needs; volatility and disruption in the global capital and credit markets; acceptance of our products among physicians and other healthcare providers; competition with other providers of diagnostic products; adverse actions or delays in new product reviews or related to currently-marketed products by the U.S. Food and Drug Administration (the "FDA"); changes in government policies; compliance with other government regulations, such as safe working conditions, manufacturing practices, environmental protection, fire hazard and disposal of hazardous substances; third-party reimbursement policies; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance and exposure to other litigation claims; interruption to our computer systems; competition for and loss of management and key personnel; international risks, including but not limited to, compliance with product registration requirements, exposure to currency exchange fluctuations and foreign currency exchange risk sharing arrangements, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, political and economic instability, taxes, and diversion of lower priced international products into U.S. markets; our significant debt service requirements; the possibility that we may incur additional indebtedness; dilution resulting from future sales of our equity; volatility in our stock price; provisions in our charter documents, Delaware law and our convertible senior notes that might delay or impede stockholder actions with respect to business combinations or similar transactions; and our intention of not paying dividends. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," "plan," "intend," "goal," "project," "strategy," "future," and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (the "SEC") from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. Except as required by law, we undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.

Quidel Contact: Quidel Corporation Randy Steward Chief Financial Officer 858.552.7931 Media and Investors Contact: Quidel Corporation Ruben Argueta 858.646.8023 Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 72

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 117

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 86

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 25

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 32

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Earnings: Barfresh Food Group's Upcoming Report

Updated Category News Views 61

Anticipating Earnings: Barfresh Food Group's Upcoming Report Barfresh Food Group (NASDAQ: BRFH) is on the brink of releasing its quarterly earnings. Investors are keenly awaiting the announcement, scheduled for Thursday. As the date approaches, it is crucial to analyze the expectations and historical performance of the company. The consensus among analysts is that...

Continue Reading
Meta's Smart Glasses: AI Performance Lags Behind ChatGPT's

Updated Category News Views 563

Meta's AI Tools Tested Against ChatGPT Recently, Gene Munster from Deepwater Asset Management conducted a head-to-head comparison of Meta Platforms Inc.'s AI capabilities on its smart glasses and the performance of OpenAI's ChatGPT. His findings highlighted significant gaps between the two AI systems. ChatGPT Outshines Meta AI in Tests During the evaluation, Munster...

Continue Reading
Tractor Supply Company Expands Offerings with Allivet Acquisition

Updated Category News Views 79

Tractor Supply Company to Acquire Allivet Tractor Supply Company (NASDAQ: TSCO), the top retailer for rural lifestyle in the U.S., has made an exciting announcement regarding its latest acquisition. The company has signed a definitive agreement to acquire Allivet, an esteemed private online pharmacy specializing in pet and animal health. This strategic move aims to...

Continue Reading
20+ Companies Break Ground in Urticaria Treatment Innovations

Updated Category News Views 236

Overview of Urticaria Treatment Innovations Urticaria, commonly known as hives, is a skin condition characterized by raised, itchy welts that can vary in size and location. The increasing prevalence of urticaria has spurred significant growth in treatment options, with various companies leading clinical trials dedicated to developing new therapies. Factors contributing to...

Continue Reading
Alphabet's Unique AI Strategy: A Competitive Edge Over Rivals

Updated Category News Views 241

Alphabet's AI Transformation and Competitive Advantage Alphabet Inc. (NASDAQ: GOOGL), a leader in technology innovation, is transforming its approach to artificial intelligence. The company, trading at $319.08 per share and boasting a market capitalization of $3.79 trillion, is narrowing the valuation gap with notable competitors. Its advancements in Tensor Processing...

Continue Reading